Home Healthcare Pharmaceuticals Cholangiocarcinoma Market

Cholangiocarcinoma Market Size, Share & Trends Analysis Report By Cancer Type (Intrahepatic CCA, Extrahepatic CCA), By Treatment Type (Chemotherapy, Immunotherapy, Targeted therapy, Radiation Therapy, Surgical Treatment, Palliative Care), By Biomarker (FGFR2, IDH1, BRAF, HER2, NTRK, RET) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: November 13, 2026 | Author: Straits Research Team | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Cholangiocarcinoma Market, By Cancer Type 2025-2034 (USD MILLION/ Units)
    1. Intrahepatic CCA
    2. Extrahepatic CCA
  2. Cholangiocarcinoma Market, By Treatment Type 2025-2034 (USD MILLION/ Units)
    1. Chemotherapy
    2. Immunotherapy
    3. Targeted therapy
    4. Radiation Therapy
    5. Surgical Treatment
    6. Palliative Care
  3. Cholangiocarcinoma Market, By Biomarker 2025-2034 (USD MILLION/ Units)
    1. FGFR2
    2. IDH1
    3. BRAF
    4. HER2
    5. NTRK
    6. RET
  4. Regional Cholangiocarcinoma Market
    1. North America
      1. North America Cholangiocarcinoma Market By Cancer Type 2025-2034 (USD MILLION/ Units)
        1. Intrahepatic CCA
        2. Extrahepatic CCA
      2. North America Cholangiocarcinoma Market By Treatment Type 2025-2034 (USD MILLION/ Units)
        1. Chemotherapy
        2. Immunotherapy
        3. Targeted therapy
        4. Radiation Therapy
        5. Surgical Treatment
        6. Palliative Care
      3. North America Cholangiocarcinoma Market By Biomarker 2025-2034 (USD MILLION/ Units)
        1. FGFR2
        2. IDH1
        3. BRAF
        4. HER2
        5. NTRK
        6. RET
      4. U.S.
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      5. Canada
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
    2. Europe
      1. Europe Cholangiocarcinoma Market By Cancer Type 2025-2034 (USD MILLION/ Units)
        1. Intrahepatic CCA
        2. Extrahepatic CCA
      2. Europe Cholangiocarcinoma Market By Treatment Type 2025-2034 (USD MILLION/ Units)
        1. Chemotherapy
        2. Immunotherapy
        3. Targeted therapy
        4. Radiation Therapy
        5. Surgical Treatment
        6. Palliative Care
      3. Europe Cholangiocarcinoma Market By Biomarker 2025-2034 (USD MILLION/ Units)
        1. FGFR2
        2. IDH1
        3. BRAF
        4. HER2
        5. NTRK
        6. RET
      4. U.K.
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      5. Germany
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      6. France
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      7. Spain
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      8. Italy
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      9. Russia
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      10. Nordic
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      11. Benelux
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      12. Rest of Europe
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
    3. APAC
      1. APAC Cholangiocarcinoma Market By Cancer Type 2025-2034 (USD MILLION/ Units)
        1. Intrahepatic CCA
        2. Extrahepatic CCA
      2. APAC Cholangiocarcinoma Market By Treatment Type 2025-2034 (USD MILLION/ Units)
        1. Chemotherapy
        2. Immunotherapy
        3. Targeted therapy
        4. Radiation Therapy
        5. Surgical Treatment
        6. Palliative Care
      3. APAC Cholangiocarcinoma Market By Biomarker 2025-2034 (USD MILLION/ Units)
        1. FGFR2
        2. IDH1
        3. BRAF
        4. HER2
        5. NTRK
        6. RET
      4. China
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      5. Korea
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      6. Japan
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      7. India
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      8. Australia
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      9. Taiwan
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      10. South East Asia
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      11. Rest of Asia-Pacific
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
    4. Middle East and Africa
      1. Middle East and Africa Cholangiocarcinoma Market By Cancer Type 2025-2034 (USD MILLION/ Units)
        1. Intrahepatic CCA
        2. Extrahepatic CCA
      2. Middle East and Africa Cholangiocarcinoma Market By Treatment Type 2025-2034 (USD MILLION/ Units)
        1. Chemotherapy
        2. Immunotherapy
        3. Targeted therapy
        4. Radiation Therapy
        5. Surgical Treatment
        6. Palliative Care
      3. Middle East and Africa Cholangiocarcinoma Market By Biomarker 2025-2034 (USD MILLION/ Units)
        1. FGFR2
        2. IDH1
        3. BRAF
        4. HER2
        5. NTRK
        6. RET
      4. UAE
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      5. Turkey
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      6. Saudi Arabia
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      7. South Africa
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      8. Egypt
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      9. Nigeria
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      10. Rest of MEA
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
    5. LATAM
      1. LATAM Cholangiocarcinoma Market By Cancer Type 2025-2034 (USD MILLION/ Units)
        1. Intrahepatic CCA
        2. Extrahepatic CCA
      2. LATAM Cholangiocarcinoma Market By Treatment Type 2025-2034 (USD MILLION/ Units)
        1. Chemotherapy
        2. Immunotherapy
        3. Targeted therapy
        4. Radiation Therapy
        5. Surgical Treatment
        6. Palliative Care
      3. LATAM Cholangiocarcinoma Market By Biomarker 2025-2034 (USD MILLION/ Units)
        1. FGFR2
        2. IDH1
        3. BRAF
        4. HER2
        5. NTRK
        6. RET
      4. Brazil
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      5. Mexico
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      6. Argentina
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      7. Chile
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      8. Colombia
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
      9. Rest of LATAM
        1. Intrahepatic CCA
        2. Extrahepatic CCA
        3. Chemotherapy
        4. Immunotherapy
        5. Targeted therapy
        6. Radiation Therapy
        7. Surgical Treatment
        8. Palliative Care
        9. FGFR2
        10. IDH1
        11. BRAF
        12. HER2
        13. NTRK
        14. RET
Report Details
−
Trusted by Industry Leaders
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com
custom reports
Need a Tailored Report?
80% of our existing clients ask for tailored reports.
Request Customization

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.